This is a multi-center, single-arm, phase II clinical study designed to observe and evaluate the effectiveness and safety of adebrelimab combined with albumin paclitaxel and nedaplatin as neoadjuvant therapy for locally advanced resectable esophageal squamous cell carcinoma.
Age: 18 to 75 years old, no limit to male or female;
Surgically resectable locally advanced esophageal squamous cell carcinoma confirmed by histology or cytology (clinical stage: stage IIa-IIIb);
Have measurable lesions and meet RECIST v1.1) standards;
Have not received any anti-tumor systemic treatment for esophageal cancer in the past;
Patients with locked lymph node metastasis;
Have a history of other malignant tumors in the past 5 years, except for cervical carcinoma in situ or cutaneous squamous cell carcinoma that has been fully treated, or basal cell carcinoma of the skin that has been basically controlled;
Suffering from bleeding disorders or a history of bleeding disorders;
Have undergone major surgery or serious trauma within 4 weeks before taking the study drug for the first time;